title: The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate.
abstract: Celiac disease (CD) is a common chronic immune disease triggered by gluten. Gliadin peptides pass through the epithelial layers, either paracellularly or transcellularly, to launch a potent adaptive immune response in the lamina propria. This aberrant immune response leads to diverse gastrointestinal and extra-gastrointestinal symptoms. Currently, the only treatment for CD is a strict lifelong adherence to a gluten-free diet (GFD), which can be challenging. An early effect of gluten in CD is an increase in gut permeability. Larazotide acetate, also known as AT-1001, is a synthetic peptide developed as a permeability regulator primarily targeting CD. In vitro studies indicate that larazotide acetate is capable of inhibiting the actin rearrangement caused by gliadin and clinical studies have been conducted using this peptide as a therapy for CD.
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
authors.forename: Shahryar
authors.initials: S
authors.lastname: Khaleghi
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
authors.forename: Josephine M
authors.initials: JM
authors.lastname: Ju
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
authors.forename: Abhinav
authors.initials: A
authors.lastname: Lamba
authors.affiliation: Professor of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Murray
keywords: Caco-2 cells; gliadin; gluten-free diet; intestinal integrity; paracellular permeability; zonulin